Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01943409 | Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils | completed | Phase 4 | 303 | Johane AllardOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02405858 | A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | completed | Phase 4 | 51 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05848947 | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA(MAApping) | completed | Phase 4 | 5 | Sirtex MedicalINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06665737 | Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients(G-CSF in NHL) | not yet recruiting | Phase 4 | 126 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04524442 | Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | completed | Phase 4 | 42 | Advanced Accelerator ApplicationsINDUSTRY | 4 | Jan 24, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT06697782 | Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer | completed | Phase 4 | 600 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06785974 | Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis(SPIRAL) | not yet recruiting | Phase 4 | 140 | Erasmus Medical CenterOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study | not yet recruiting | Phase 4 | 30 | Fujian Medical University Union HospitalOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06784986 | Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.(ARCO2) | recruiting | Phase 4 | 200 | Brazilian Institute of Robotic SurgeryOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04134208 | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer | terminated | Phase 4 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06777537 | Neoadjuvant Chemotherapy with or Without Talniflumate for the Treatment of Breast Cancer | not yet recruiting | Phase 4 | 200 | Shandong UniversityOTHER | 0 | Jan 16, 2025 | clinicaltrials |
| NCT06679816 | Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors | recruiting | Phase 4 | 882 | Beijing Tiantan HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06761911 | BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma | not yet recruiting | Phase 4 | 100 | Xiuhua SunOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT05568537 | Prostate MRI and Pylarify PSMA PET/CT | withdrawn | Phase 4 | 0 | Corewell Health EastOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT05717400 | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy | terminated | Phase 4 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05894694 | Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer | recruiting | Phase 4 | 320 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06734598 | Efficacy of Botox Injection of the Masticatory Muscles in Head &Neck Cancer Patients with Trismus After Radiotherapy | recruiting | Phase 4 | 120 | National Taiwan University HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03752216 | NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.(NiQoLe) | completed | Phase 4 | 141 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06726291 | Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer(NOEME) | recruiting | Phase 4 | 84 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02918968 | Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | completed | Phase 4 | 206 | Astellas Pharma IncINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT02116582 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 4 | 215 | Astellas Pharma Europe B.V.INDUSTRY | 5 | Dec 6, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03564938 | Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC). | completed | Phase 4 | 100 | BayerINDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06711679 | Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia | enrolling by invitation | Phase 4 | 180 | Yilin ZhaoOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06706921 | 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer | recruiting | Phase 4 | 15 | VA Greater Los Angeles Healthcare SystemFED | 1 | Nov 27, 2024 | clinicaltrials |
| NCT03035032 | A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients | completed | Phase 4 | 107 | Astellas Pharma Singapore Pte. Ltd.INDUSTRY | 8 | Nov 26, 2024 | clinicaltrials |
| NCT04657679 | Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts(LEANORA) | terminated | Phase 4 | 21 | Georgetown UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.(ABLE-42) | withdrawn | Phase 4 | 0 | Ferring PharmaceuticalsINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06252662 | Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies | recruiting | Phase 4 | 200 | United States Naval Medical Center, PortsmouthFED | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06023368 | Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray | withdrawn | Phase 4 | 0 | Marianne HuttiOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03024684 | Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment(SHOT) | active not recruiting | Phase 4 | 240 | Chiayi Christian HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05688384 | Patient-Controlled Sedation in Port Implantation (PACSPI-2)(PACSPI-2) | completed | Phase 4 | 340 | Region Jönköping CountyOTHER_GOV | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06665334 | To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery | not yet recruiting | Phase 4 | 134 | Fudan UniversityOTHER | 0 | Oct 31, 2024 | clinicaltrials |
| NCT05806580 | Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 4 | 8 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05784311 | Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)(SPARROW) | recruiting | Phase 4 | 344 | Leiden University Medical CenterOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05629494 | Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test(ADAPT-PSA) | recruiting | Phase 4 | 198 | Albany Medical CollegeOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06353126 | DEB-TACE Prior to Liver Transplantation in the Treatment of HCC | recruiting | Phase 4 | 40 | RenJi HospitalOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04258631 | Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies | completed | Phase 4 | 105 | Mayo ClinicOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06609304 | Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma(axi-cel) | recruiting | Phase 4 | 20 | Zhengzhou UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06640738 | Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation | not yet recruiting | Phase 4 | 60 | Kaohsiung Medical UniversityOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06641544 | The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer(IFANS) | recruiting | Phase 4 | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | terminated | Phase 4 | 12 | Indiana UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05250648 | Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)(GECOP-MMC) | recruiting | Phase 4 | 216 | Hospital Universitario de FuenlabradaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2025source: clinicaltrials